Group 1 - Northern Rare Earth reported a net profit increase of 280% year-on-year for the first three quarters, driven by higher sales volume and prices of rare earth products [1] - Postal Savings Bank has received approval to establish a financial asset investment company with a registered capital of 10 billion yuan, aimed at enhancing comprehensive service capabilities and supporting technological innovation [2] - Silyus announced a maximum price of HKD 131.5 per share for its H-share issuance, with a total of 100.2 million shares available for global offering [3] Group 2 - Hengtong Optic-Electric won a bid for marine energy projects with a total contract value of 1.868 billion yuan, including the supply and construction of undersea cables [4] - Western Mining's subsidiary Yulong Copper won exploration rights for the Chating copper polymetallic mine for 8.609 billion yuan, which is expected to enhance the company's resource reserves [5] - China Bank appointed Liu Chenggang as vice president, effective from October 24, 2025 [6] Group 3 - ST Guangwu announced the removal of other risk warnings for its stock, changing its name to Guanghui Logistics, which will allow for a wider trading limit [7] - Wireless Media set an initial transfer price of 29.11 yuan per share for its inquiry transfer, with a subscription multiple of 2.01 times [8][9] - Jiangshan Oupai's subsidiaries in Henan and Chongqing will cease operations due to insufficient orders, with business transferred to its Zhejiang base [10] Group 4 - Zhenyu Technology plans to invest 2.11 billion yuan in precision component manufacturing and humanoid robot projects, with the first phase of investment to be signed soon [11] - Jinyuan Co. announced the resignation of its general manager, with Qiu Yongping appointed as the new general manager [12] Group 5 - CanSino reported a net profit of 27.93 million yuan for Q3, a year-on-year increase of 842.01% [13] - Jiangshan Co. reported a net profit of 86.73 million yuan for Q3, a year-on-year increase of 11,890.01% [14] - Yingshi Innovation reported a net profit of 272 million yuan for Q3, a year-on-year decrease of 15.90% [15] Group 6 - Chip Origin reported a net loss of 26.85 million yuan for Q3, despite a revenue increase of 78.38% [16] - Tonghua Dongbao reported a net profit of 984 million yuan for Q3, a year-on-year increase of 499.86% [17] - Hengrui Medicine reported a net profit of 1.301 billion yuan for Q3, a year-on-year increase of 9.53% [18] Group 7 - Zhongguang Lightning reported a net profit of 6.46 million yuan for Q3, a year-on-year increase of 382.66% [19] - Ice River Network reported a net profit of 166 million yuan for Q3, a year-on-year increase of 244.58% [20] - Daheng Technology reported a net profit of 71.48 million yuan for Q3, a year-on-year increase of 1,960.72% [21] Group 8 - Yanjin Puzhi reported a net profit of 232 million yuan for Q3, a year-on-year increase of 33.55% [22] - Sichuan Gold reported a net profit of 160 million yuan for Q3, a year-on-year increase of 184.38% [23] - Sanbo Brain Science reported a net profit of 13.93 million yuan for Q3, a year-on-year decrease of 63.26% [24] Group 9 - Hengli Petrochemical reported a net profit of 1.972 billion yuan for Q3, a year-on-year increase of 81.47% [25] - Deepin Technology reported a net profit of 147 million yuan for Q3, a year-on-year increase of 1,097.40% [26] - Huisheng Biological reported a net profit of 70.72 million yuan for Q3, a year-on-year increase of 1,575.79% [27] Group 10 - Gaode Infrared reported a net profit of 401 million yuan for Q3, a year-on-year increase of 1,143.72% [28] - Qingdao Beer reported a net profit of 1.37 billion yuan for Q3, a year-on-year increase of 1.62% [29] - Nanjing Public Utilities reported a net profit of 84.62 million yuan for Q3, a year-on-year increase of 2,492.12% [30] Group 11 - Zhangyuan Tungsten reported a net profit of 75.02 million yuan for Q3, a year-on-year increase of 118.56% [31] - Yongmaotai reported a net profit of 30.41 million yuan for Q3, a year-on-year increase of 6,319.92% [32] Group 12 - Tongrun Equipment announced that two shareholders plan to reduce their holdings by 1.50% each, totaling a maximum of 3.00% [33] - High-speed Rail Electric announced a pre-bid for a city rail transit project worth 62.39 million yuan [34]

Core Viewpoint - Tonghua Dongbao (600867) reported significant growth in revenue and net profit for the first three quarters of 2025, indicating a strong financial performance driven by increased sales and investment gains [1] Financial Performance - The company achieved an operating revenue of 2.18 billion yuan, representing a year-on-year increase of 50.55% [1] - The net profit attributable to shareholders reached 1.202 billion yuan, marking a turnaround from losses in the previous year [1] Factors Influencing Growth - The increase in net profit is primarily attributed to the growth in operating revenue and gains from the transfer of shares in Te Bao Biological [1]

证券代码：600867 证券简称：通化东宝 公告编号：2025-074 通化东宝药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 18 日至 11 月 24 日前登录上证路演中心网站首 页点击"提问预征集"栏目或通过公司邮箱（thdb600867@thdb.com）进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 通化东宝药业股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日 发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 25 日 14:00-15:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务指标的具体情 ...

关于计提资产减值准备和核销资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通化东宝药业股份有限公司（以下简称"公司""通化东宝"）于 2025 年 10 月 27 日召开第十一届董事会第十九次会议，审议通过了《关于计提资产减值准 备和核销资产的议案》，为了更加客观、公正地反映公司财务状况和资产价值， 根据《企业会计准则》等相关规定，结合企业实际经营情况和资产现状，对 2025 年 9 月 30 日相关资产进行了减值迹象的识别，对于其中已出现减值迹象的进行 了减值测试，并根据测试结果计提相关资产减值准备，在 2025 年 1-6 月已计提 资产减值准备的基础上，公司 2025 年 7-9 月计提资产减值准备和核销资产的具 体情况如下： 证券代码：600867 证券简称：通化东宝 公告编号：2025-073 通化东宝药业股份有限公司 一、本次计提资产减值准备和核销资产的概述 为更加真实、准确地反映公司 2025 年第三季度的财务状况、资产价值及经 营成果，基于谨慎性原则，公司对相关资产进行了减值测试。根据减值测试结果， ...

第十一届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 通化东宝药业股份有限公司（以下简称"公司"或"通化东宝"）第十一届 董事会第十九次会议，于 2025 年 10 月 27 日以通讯方式召开，会议通知于 2025 年 10 月 17 日，以书面、电子邮件等形式发出。本次会议应参加会议董事 9 人， 实际出席会议董事 9 人，会议由董事长李佳鸿先生主持，监事及高级管理人员列 席了会议。会议符合《公司法》和《公司章程》的有关规定，所作决议合法有效。 会议审议并通过了如下决议： （二）审议通过了《关于计提资产减值准备和核销资产的议案》。 证券代码：600867 证券简称：通化东宝 公告编号：2025-072 通化东宝药业股份有限公司 二、董事会会议审议情况 （一）审议通过了《2025 年第三季度报告》； 表决结果：同意 9 票 反对 0 票 弃权 0 票 本议案已经公司董事会审计委员会审议通过。 内容详见公司于 2025 年 10 月 28 日在中国证券报、上海证券报及上海证券 ...

Group 1 - The company Tonghua Dongbao announced a provision for asset impairment totaling 63.49 million yuan for the period from July to September 2025, with an asset write-off amounting to 51.54 million yuan, which will reduce the net profit attributable to shareholders by approximately 107 million yuan after tax effects [1][1][1] - For the first half of 2025, the revenue composition of Tonghua Dongbao was as follows: 98.59% from the pharmaceutical industry, 1.27% from other businesses, and 0.14% from the real estate sector [1][1][1] - As of the report date, Tonghua Dongbao's market capitalization stood at 17.6 billion yuan [1][1][1]

Financial Performance - The company's revenue for the third quarter reached ¥806,097,911.72, representing a year-on-year increase of 13.90% and a cumulative increase of 50.55% year-to-date[4] - The total profit for the year-to-date period was ¥1,185,631,865.28, showing a significant increase of 547.29% compared to the previous year[4] - The net profit attributable to shareholders for the third quarter was ¥984,476,304.01, reflecting a year-on-year increase of 499.86%[4] - The net profit excluding non-recurring gains and losses for the third quarter was ¥100,539,622.11, down 32.24% year-on-year, primarily due to losses from a terminated project[4][10] - Basic and diluted earnings per share for the third quarter were both ¥0.50, an increase of 525.00% year-on-year[5] - Total operating revenue for the first three quarters of 2025 reached CNY 2,179,588,480.01, a significant increase of 50.5% compared to CNY 1,447,720,331.65 in the same period of 2024[25] - The total operating profit for the first three quarters of 2025 was CNY 1,492,757,250.23, compared to a loss of CNY 136,892,789.30 in the same period of 2024[26] - The net profit attributable to shareholders of the parent company reached CNY 1,202,234,367.84, while the net loss was CNY 66,372,427.80 in the previous year[26] - The basic and diluted earnings per share for the current period were CNY 0.61, compared to a loss of CNY 0.03 per share in the same period last year[28] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥380,247,605.21, an increase of 68.88% compared to the previous year[5] - The company's cash and cash equivalents rose to CNY 1,499,224,069.89 as of September 30, 2025, compared to CNY 586,595,200.23 at the end of 2024, representing an increase of 155.5%[21] - The total cash and cash equivalents at the end of the period amounted to CNY 1,499,224,069.89, compared to CNY 332,825,326.83 at the end of the previous year[30] - Cash flow from operating activities generated a net amount of CNY 380,247,605.21, an increase from CNY 225,162,475.15 in the prior year[29] - Cash flow from investing activities showed a net inflow of CNY 904,936,747.69, a significant improvement from a net outflow of CNY 455,059,932.22 in the previous year[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 82,143[12] - Dongbao Industrial Group Co., Ltd. holds 613,823,496 shares, accounting for 31.34% of the total shares, with 565,939,472 shares pledged[12] - Tianjin Zhenyi Equity Investment Partnership holds 183,058,967 shares, representing 9.35% of the total shares[12] - The company plans to transfer 23,187,600 shares of Xiamen Te Bao Bioengineering Co., Ltd. at a price of RMB 56.12 per share, totaling RMB 1,301,288,112[14] - Dongbao Industrial Group plans to increase its shareholding by at least 1% (19,817,341 shares) and up to 2% (39,634,681 shares) within 12 months starting from October 31, 2024[15] - As of October 27, 2025, 22,124,109 shares have been acquired, representing 1.13% of the current total shares[15] - The company approved the 2025 Employee Stock Ownership Plan, with 9,290,000 shares transferred at a price of RMB 4.29 per share[16][17] - The company plans to repurchase shares with a total fund of no less than RMB 20 million and no more than RMB 40 million, aiming to buy back between 200,000 and 400,000 shares[18] - The repurchase price will not exceed RMB 10 per share[18] Investment and R&D - Research and development expenses increased to CNY 116,429,133.17 in the first three quarters of 2025, compared to CNY 75,087,241.78 in 2024, marking a rise of 55%[25] - Investment income for the first three quarters of 2025 was CNY 1,172,543,410.66, a substantial increase from CNY 88,862,833.72 in the same period of 2024[25] - The company reported a non-recurring gain of ¥883,936,681.90 for the year-to-date period, primarily from the transfer of shares in a subsidiary[10] Market and Inventory - The significant increase in revenue was driven by a notable rise in sales of insulin analog products and breakthroughs in overseas markets[9] - The total inventory as of September 30, 2025, was CNY 740,523,999.80, slightly up from CNY 736,309,312.91 at the end of 2024, indicating stable inventory management[21] - The company's total liabilities increased to CNY 1,016,128,667.09 as of September 30, 2025, compared to CNY 978,084,292.41 at the end of 2024, reflecting a rise of 3.9%[23] Future Outlook - The net profit for the first three quarters of 2025 is expected to show a significant improvement due to increased revenue and investment income, although specific guidance was not provided[25] - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the upcoming quarters[25] Accounting Standards - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the current year[31]

Core Viewpoint - Tonghua Dongbao (600867.SH) reported significant growth in revenue and net profit for the third quarter of 2025, driven by increased sales of insulin analog products and successful overseas business expansion [1] Financial Performance - For the first three quarters, the company achieved a revenue of 2.18 billion yuan, representing a year-on-year increase of 50.55% [1] - The net profit attributable to shareholders for the same period was 1.20 billion yuan [1] - In the third quarter alone, the company recorded a revenue of 806 million yuan, with a year-on-year growth of 13.90% [1] - The net profit for the third quarter reached 984 million yuan, showing a remarkable year-on-year increase of 499.86% [1] Business Drivers - The substantial growth in performance is primarily attributed to the significant increase in sales of insulin analog products, which boosted domestic sales revenue [1] - The company also experienced multiple breakthroughs in overseas business, contributing to increased export revenue [1] - Additionally, the transfer of shares in Te Bao Bio resulted in substantial gains, further enhancing the company's financial performance [1]

Core Insights - Tonghua Dongbao reported a revenue of 806 million yuan for Q3 2025, marking a year-on-year increase of 13.90% [1] - The net profit attributable to shareholders reached 984 million yuan, showing a significant year-on-year growth of 499.86% [1] - Basic earnings per share stood at 0.5 yuan [1] Financial Performance - For the first three quarters, the company achieved a total revenue of 2.18 billion yuan, reflecting a year-on-year growth of 50.55% [1] - The net profit attributable to shareholders for the same period was 1.202 billion yuan [1]

Core Insights - The company reported a third-quarter revenue of 806 million, representing a year-on-year increase of 13.90% [1] - The net profit for the third quarter reached 984 million, showing a significant year-on-year growth of 499.86% [1] - For the first three quarters, the total revenue amounted to 2.18 billion, reflecting a year-on-year increase of 50.55% [1] - The net profit for the first three quarters was 1.202 billion [1]